The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...

The three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...

Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

Cigna (CI) and UnitedHealth (UNH) significantly marked up prices for specialty generic drugs over a six-year period.